INC Research Holdings, a global phase I to IV CRO, has appointed several new senior leaders to strengthen its Real World & Late Phase (RWLP) and Global Consulting offerings to biopharmaceutical customers worldwide. INC’s RWLP team is dedicated to real world, evidence-based data collection and works in close collaboration with the Company’s Global Consulting business to support customers at every stage of their product and portfolio development. INC’s expanded team will help maximize value for sponsors throughout the product lifecycle, from concept to commercialization, by providing consultative and operational expertise in the delivery of real-world evidence. The appointments reinforce INC's continued focus on providing customers with strategic consulting services along with the right evidence to make the best clinical decisions in this rapidly expanding segment of the clinical research environment.
“Healthcare stakeholders are increasingly seeking real-world evidence to support regulatory, reimbursement and prescribing decisions,” said Christian Tucat, MBA, executive vice president, RWLP and Global Consulting. “It’s never too early to have a commercial plan in drug development, and that’s why we’ve continued to grow our team. The leadership we’ve added in RWLP and Global Consulting have extensive industry connections and understand the complexities of Late Phase studies, moving new therapies from a controlled and experimental environment of a clinical trial to a real-world situation, and then to market. By beginning with the end in mind, we ensure we gain the right outcome for our sponsors as well as for patients, physicians, payers and regulators.”
The newly appointed experts to INC’s RWLP and Global Consulting teams include:
INC’s Global Consulting team provides global advisory and implementation support service for the biopharmaceutical industry. Led by a senior team, the unit is committed to working with customers to deliver innovative and practical solutions that support their business needs from concept through development to commercialization.